Jiming Ye
RMIT University, Australia
Posters & Accepted Abstracts: J Diabetes Metab
Diabetes is one of the fastest growing diseases worldwide afflicting approximately 380 million people, primarily due to a dramatic increase in type 2 diabetes. Despite major investment by pharmaceutical companies in conventional drug discovery pipelines, development of new drugs has failed to keep up with the increasing incidence of type 2 diabetes. Drug repurposing, is the process in which the existing drugs are applied to a new indication and it is gaining momentum as a successful approach to overcome the bottlenecks commonly encountered with conventional approaches. Repurposing of drugs takes advantage of available information on the molecular pharmacology of clinical agents, to drastically shorten the drug development timelines. This talk will share our recent experience in repurposing existing drugs by targeting fatty acid oxidation (energy expenditure), de novo lipogenesis, mitochondrial metabolism, AMPK, CaMKKβ, Foxo1, ER stress, HSP72 and autophagy. The repurposed drugs in our laboratory include beberines (Diabetes 57:1414, 2008), triterpenpoids (Chem Biol 15:263, 2008; PlosOne 9:e10723, 2014), rutaecarpines (ACS Chem Biol 8:2301, 2013; J Med Chem 58:9395, 2015) matrine (Bri J Pharmacol 172:4303, 2015; BBA 1852:156, 2015). As well as revealing the new cellular targets for re-evaluation of the molecular mode of action for the treatment of diabetes, this presentation will also discuss relevant cell (Biochem Pharmacol 84: 830, 2012) and animal (PlosOne 7: e42115, 2012) models used in our studies in the screening process for this strategy.
Email: jiming.ye@rmit.edu.au
